Advertisement
NEW YORK, Fev. 7, 2018 /PRNewswire/ -- Read the full report: https://www.reportlinker.com/p04678775
SummaryNational Cancer Institute (NCI) defines Melanoma as a form of cancer that begins in melanocytes (cells that make the pigment melanin) and that may begin in a nevus (mole) (skin melanoma) or in other pigmented tissues, such as the eye or the intestines (NCI, 2014). Melanoma is often considered to be one of the most aggressive and treatment-resistant human cancers, and despite significant advances in melanoma therapy, it remains the deadliest form of skin cancer, with a five-year survival rate of only 15% (Tsao, et al. 2012; Zhang et al., 2015).Currently, there are a limited number of approved drugs for melanoma, with the most successful by far being Opdivo (nivolumab). This is an immunotherapeutic indicated for the treatment of advanced melanoma – among numerous other oncological indications – and acts to slow tumor growth and metastasis. Approval for the treatment of melanoma was granted in 2014 due to reduced toxicity and an improved response rate compared with other therapeutic options.Melanoma Therapeutic pipeline is moderately sized, with 579 programs active across all stages of development, but is much larger than the current melanoma market of 130 products. The range of mechanisms of action employed by these compounds is also highly diverse, more so than in the current market landscape.Melanoma Therapeutic deals landscape is moderately active, with the mean value for co-development deals in 2016 standing at USD304m, which is below the industry average, and the mean value of licensing deals also falling below the industry average, at US$164m, as highlighted. This reflects the low proportion of first-in-class programs involved in deals; the majority of deals involved currently established targets, and there are 176 first-in-class programs not involved in prior deals.In spite of these developments, there are still significant unmet needs for both cutaneous and extra cutaneous melanoma, and the rationale for investment in first-in-class innovation remains strong. First-in-class products account for a considerable proportion of the melanoma pipeline, which is substantially larger than the current market.The report "Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation" provides you to understand current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment strategies currently available. Furthermore, it will help to analyze the melanoma pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target and identifies commercial opportunities in the melanoma deals landscape by analyzing trends in licensing and co-development deals and assessing melanoma therapies that are not yet involved in deals, and may be potential investment opportunities.ScopeRising global prevalence and unmet need have resulted in an increase in developmental interest- What is the pathophysiology of melanoma? - How has the emergence of new drug classes in the past decade impacted the treatment algorithm? - What are the most significant unmet needs within the market? The melanoma pipeline is large and innovative in comparison with the current market- Which molecule types and molecular targets are most prominent within the pipeline? - Which first-in-class targets are most promising? - How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class? - Do melanoma products attract high deal values? - Which molecule types and molecular targets dominate the deals landscape? - Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?Reasons to buy- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment strategies currently available.- Visualize the composition of the melanoma market in terms of the dominant classes of therapies. Unmet needs are highlighted to allow a competitive understanding of current gaps in the market.- Analyze the melanoma pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are signs in the pipeline that the industry is seeking novel approaches to meet unmet needs within melanoma.- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising novel targets have been further reviewed in greater detail.- Identify commercial opportunities in the melanoma deals landscape by analyzing trends in licensing and co-development deals and assessing melanoma therapies that are not yet involved in deals, and may be potential investment opportunities.Read the full report: https://www.reportlinker.com/p04678775
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
View original content:http://www.prnewswire.com/news-releases/frontier-pharma-melanoma-therapeutics---cytokine-and-multiple-targeted-small-molecules-and-mabs-dominate-pipeline-and-first-in-class-innovation-300594997.html
SOURCE Reportlinker
